Indication
Inflammatory Diseases
2 clinical trials
3 products
Clinical trial
A Phase 1, Open-label, Sequential-group, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 592 Administered Subcutaneously in Healthy Chinese, Japanese, and Caucasian SubjectsStatus: Completed, Estimated PCD: 2022-10-03
Product
Efavaleukin alfaProduct
PlaceboProduct
AZD6793